team size
funding probability score
total disclosed funding
last round valuation estimate
disclosed funding rounds
latest round
latest funding stage
next round estimate
development stage
number of investors
number of competitors
monthly web visits
twitter followers
HQ address
Established since 2007, AnyGenes\u00ae is privately owned biotechnology company. Involved in research and development, manufacturing, production and sales of signaling pathways for biomarkers discovery and validation. Our fast growing databases of over thousands of validated factors are now available. They represent signaling pathways (SignArrays\u00ae) of different cellular processes (cell cycle, apoptosis, autophagy, drug resistance, drug metabolism...), and for severe disease (cancer, neurodegenerative disease, autoimmune diseases\u2026), specifically designed to be analysed by qPCR array technology and dedicated (home designed) software data analysis. AnyGenes\u00ae products are bench controlled, easy to use, and cost effective..\r\n\r\nAnyGenes\u2019s team is composed of world-class scientists and entrepreneurs with great experience in applied research in the area of functional biology. The combination of their expertise and experience provides a unique and valuable set of complementary skills. Between them they have published over 200 articles in international scientific journals.
AnyGenes® also offers services of integrated approaches based on a broad range of technologies for severe diseases analysis (neurodegenerative diseases, cancer…) and for drug development including drug screening and testing in vitro cell culture, mechanism of action, search of biomarkers, data analysis and patient stratification. Our goal is to help in the efficient development of new personalized drugs by developing innovative tools which allow selecting patients most likely to respond to a developed targeted therapy.

AnyGenes ® has its own i) laboratories with well equipped platform and validated technology for mutation detection, copy number variation, gene expression ii) data-mining platform for SignArrays design of specific pathways, data analysis and software development:
 With the possibility of using different type of biological samples: biopsies, cell lines, PBMC, FFPE…
 Using cutting edge technologies: Next Generation Sequencing (NGS), digital PCR…
 While taking charge of the whole process from sample reception to report of complete data analysis.
 With algorithms which are adapted to the data interpretation and statistical analysis.

There is much more to this profile.
Log in or sign up for free to see the whole thing.

Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats